O	0	8	Analysis
O	9	11	of
O	12	19	cardiac
O	20	23	and
O	24	33	pulmonary
O	34	46	complication
O	47	60	probabilities
O	61	66	after
B-intervention	67	76	radiation
I-intervention	77	84	therapy
O	85	88	for
O	89	97	patients
O	98	102	with
O	103	108	early
O	108	109	-
O	109	114	stage
O	115	121	breast
O	122	128	cancer
O	128	129	.

O	130	133	The
O	134	141	purpose
O	142	144	of
O	145	149	this
O	150	155	study
O	156	159	was
O	160	162	to
O	163	171	evaluate
O	172	175	the
O	176	191	radiobiological
O	192	204	implications
O	205	207	of
O	208	216	clinical
O	217	220	use
O	221	223	of
O	224	235	respiratory
O	235	236	-
O	236	241	gated
O	242	252	techniques
O	253	256	for
O	257	270	postoperative
O	271	280	radiation
O	281	288	therapy
O	289	291	of
O	292	297	early
O	297	298	-
O	298	303	stage
O	304	308	left
O	308	309	-
O	309	314	sided
O	315	321	breast
O	322	328	cancer
O	329	334	after
O	335	341	breast
O	341	342	-
O	342	352	conserving
O	353	360	surgery
O	360	361	.

O	362	371	Radiation
O	372	379	therapy
O	380	389	treatment
O	390	395	plans
O	396	398	of
B-total-participants	399	401	80
B-eligibility	402	410	patients
I-eligibility	411	415	with
I-eligibility	416	421	early
I-eligibility	421	422	-
I-eligibility	422	427	stage
I-eligibility	428	434	breast
I-eligibility	435	441	cancer
I-eligibility	442	443	(
I-eligibility	443	448	stage
I-eligibility	449	450	I
I-eligibility	450	451	-
I-eligibility	451	453	II
I-eligibility	453	454	)
I-eligibility	454	455	,
I-eligibility	456	465	receiving
I-eligibility	466	471	whole
I-eligibility	472	478	breast
I-eligibility	479	490	irradiation
I-eligibility	491	496	after
I-eligibility	497	503	breast
I-eligibility	503	504	-
I-eligibility	504	514	conserving
I-eligibility	515	522	therapy
O	522	523	,
O	524	528	were
O	529	537	analyzed
O	537	538	.

O	539	542	The
O	543	550	control
O	551	556	group
O	557	567	consisting
O	568	570	of
B-control-participants	571	573	47
O	574	582	patients
O	583	591	received
B-control	592	600	standard
I-control	601	610	radiation
I-control	611	618	therapy
O	618	619	,
O	620	623	and
O	624	627	the
O	628	639	respiratory
O	639	640	-
O	640	645	gated
O	646	651	group
O	652	662	consisting
O	663	665	of
B-intervention-participants	666	668	33
O	669	677	patients
O	678	686	received
B-intervention	687	691	deep
I-intervention	692	703	inspiration
I-intervention	703	704	-
I-intervention	704	709	gated
I-intervention	710	719	radiation
I-intervention	720	727	therapy
O	727	728	.

O	729	735	Normal
O	736	742	tissue
O	743	755	complication
O	756	769	probabilities
O	770	771	(
O	771	775	NTCP
O	775	776	)
O	777	780	for
O	781	788	cardiac
O	789	798	mortality
O	799	802	and
O	803	806	for
O	807	815	clinical
O	816	825	radiation
O	825	826	-
O	826	833	induced
O	834	845	pneumonitis
O	846	850	were
O	851	861	calculated
O	862	865	for
O	866	869	all
O	870	878	patients
O	879	887	included
O	888	890	in
O	891	898	present
O	899	904	study
O	904	905	,
O	906	911	using
O	912	920	relative
O	921	930	seriality
O	931	936	model
O	936	937	.

O	938	942	NTCP
O	943	947	data
O	948	952	were
O	953	961	analyzed
O	962	965	for
O	966	969	113
O	970	979	radiation
O	980	987	therapy
O	988	993	plans
O	993	994	,
O	995	1000	which
O	1001	1009	included
O	1010	1014	free
O	1015	1024	breathing
O	1025	1030	plans
O	1031	1034	for
O	1035	1038	the
O	1039	1050	respiratory
O	1050	1051	-
O	1051	1056	gated
O	1057	1063	groups
O	1063	1064	.

B-outcome	1065	1076	Pneumonitis
I-outcome	1077	1088	probability
O	1089	1092	was
B-cv-bin-percent	1093	1094	0
I-cv-bin-percent	1094	1095	.
I-cv-bin-percent	1095	1096	6
I-cv-bin-percent	1096	1097	%
O	1098	1099	(
O	1099	1104	range
O	1105	1106	0
O	1106	1107	.
O	1107	1108	0
O	1108	1109	-
O	1109	1110	2
O	1110	1111	.
O	1111	1112	8
O	1112	1113	%
O	1113	1114	)
O	1115	1118	and
B-iv-bin-percent	1119	1120	0
I-iv-bin-percent	1120	1121	.
I-iv-bin-percent	1121	1122	3
I-iv-bin-percent	1122	1123	%
O	1124	1125	(
O	1125	1126	0
O	1126	1127	.
O	1127	1128	0
O	1128	1129	-
O	1129	1130	1
O	1130	1131	.
O	1131	1132	2
O	1132	1133	%
O	1133	1134	)
O	1135	1138	for
O	1139	1146	control
O	1147	1150	and
O	1151	1162	respiratory
O	1162	1163	-
O	1163	1168	gated
O	1169	1174	group
O	1174	1175	,
O	1176	1188	respectively
O	1188	1189	.

B-outcome	1190	1197	Cardiac
I-outcome	1198	1207	mortality
O	1208	1211	was
B-cv-bin-percent	1212	1213	1
I-cv-bin-percent	1213	1214	.
I-cv-bin-percent	1214	1215	3
I-cv-bin-percent	1215	1216	%
O	1217	1218	(
O	1218	1219	0
O	1219	1220	.
O	1220	1221	0
O	1221	1222	-
O	1222	1223	5
O	1223	1224	.
O	1224	1225	0
O	1225	1226	%
O	1226	1227	)
O	1228	1231	and
B-iv-bin-percent	1232	1233	0
I-iv-bin-percent	1233	1234	.
I-iv-bin-percent	1234	1235	2
I-iv-bin-percent	1235	1236	%
O	1237	1238	(
O	1238	1239	0
O	1239	1240	.
O	1240	1241	0
O	1241	1242	-
O	1242	1243	2
O	1243	1244	.
O	1244	1245	8
O	1245	1246	%
O	1246	1247	)
O	1248	1251	for
O	1252	1259	control
O	1260	1263	and
O	1264	1275	respiratory
O	1275	1276	-
O	1276	1281	gated
O	1282	1287	group
O	1287	1288	,
O	1289	1301	respectively
O	1301	1302	.

O	1303	1308	Using
O	1309	1320	respiratory
O	1320	1321	-
O	1321	1326	gated
O	1327	1336	radiation
O	1337	1344	therapy
O	1344	1345	,
B-outcome	1346	1350	NTCP
O	1351	1354	was
O	1355	1362	reduced
O	1363	1365	in
O	1366	1376	comparison
O	1377	1381	with
O	1382	1385	the
O	1386	1393	control
O	1394	1399	group
O	1400	1402	by
B-cv-bin-percent	1403	1405	83
I-cv-bin-percent	1405	1406	%
O	1407	1408	(
O	1408	1409	P
O	1409	1410	<
O	1410	1411	0
O	1411	1412	.
O	1412	1417	00001
O	1417	1418	)
O	1419	1422	and
O	1423	1425	by
B-iv-bin-percent	1426	1428	55
I-iv-bin-percent	1428	1429	%
O	1430	1431	(
O	1431	1432	P
O	1432	1433	=
O	1433	1434	0
O	1434	1435	.
O	1435	1440	01270
O	1440	1441	)
O	1442	1445	for
O	1446	1453	cardiac
O	1454	1463	mortality
O	1464	1467	and
O	1468	1471	for
O	1472	1480	clinical
O	1481	1490	radiation
O	1490	1491	-
O	1491	1498	induced
O	1499	1510	pneumonitis
O	1510	1511	,
O	1512	1524	respectively
O	1524	1525	.

O	1526	1529	Use
O	1530	1532	of
O	1533	1544	respiratory
O	1544	1545	-
O	1545	1550	gated
O	1551	1560	radiation
O	1561	1568	therapy
O	1568	1569	,
O	1570	1573	for
O	1574	1587	postoperative
O	1588	1597	treatment
O	1598	1600	of
O	1601	1606	early
O	1606	1607	-
O	1607	1612	stage
O	1613	1619	breast
O	1620	1626	cancer
O	1626	1627	,
O	1628	1641	significantly
O	1642	1649	reduces
O	1650	1659	excessive
B-outcome	1660	1667	cardiac
I-outcome	1668	1677	mortality
O	1678	1689	probability
O	1690	1693	and
B-outcome	1694	1703	pulmonary
I-outcome	1704	1716	complication
O	1717	1728	probability
O	1728	1729	,
O	1730	1732	as
O	1733	1741	compared
O	1742	1744	to
O	1745	1753	standard
O	1754	1763	radiation
O	1764	1771	therapy
O	1772	1782	techniques
O	1782	1783	.

O	1784	1788	This
O	1789	1791	is
O	1792	1802	especially
O	1803	1812	important
O	1813	1817	from
O	1818	1823	heart
O	1824	1836	complication
O	1837	1848	probability
O	1849	1854	point
O	1855	1857	of
O	1858	1862	view
O	1862	1863	,
O	1864	1866	as
O	1867	1874	cardiac
O	1875	1884	mortality
O	1885	1892	remains
O	1893	1896	one
O	1897	1899	of
O	1900	1903	the
O	1904	1913	important
O	1914	1920	issues
O	1921	1923	of
O	1924	1937	postoperative
O	1938	1944	breast
O	1945	1956	irradiation
O	1957	1959	in
O	1960	1968	patients
O	1969	1973	with
O	1974	1979	early
O	1980	1985	stage
O	1986	1992	breast
O	1993	1999	cancer
O	1999	2000	.
